Skip to content Skip to main navigation


MPN heroes celebration

August 21, 2017.

Do you know someone who is a Canadian MPN Champion? Nominations are open for the Canadian Myeloproliferative Neoplasm Network 2017 MPN Heroes Celebration Event in Atlanta, GA, on December 8, 2017.  The Canadian MPN Network will recognize one MPN hero.  They may be a patient who as inspired you, a caregiver, an organization or a healthcare […]

Pacritinib clinical hold lifted

February 27, 2017.

CTI BioPharma Corp. (CTI BioPharma) announced (January 5th 2017) that the U.S. Food and Drug Administration (FDA) has lifted the full clinical hold (implemented in February 2016) on all clinical trials using the drug pacritinib. Pacritinib is a drug aimed at myelofibrosis but was placed on full clinical hold by the FDA due to safety concerns. […]

21st EHA Annual Congress: June 9-12, 2016 in Copenhagen

March 15, 2016.

The premier hematology congress in Europe offers a program covering every subspecialty in hematology and the opportunity to network with experts from all over the globe. Educational and scientific program will highlight state-of-the art clinical practice, the latest findings in hematology research and many more interesting sessions. Objectives Hematologists and affiliated professionals attending the EHA […]

Health Canada approves ruxolitinib for PV patients

February 19, 2016.

Health Canada has approved ruxolitinib (Jakavi®) for the control of hematocrit in adult patients with polycythemia vera (PV) who are resistant to or intolerant of a cytoreductive agent. Read Novartis press release

Pacritinib put on FDA hold

February 10, 2016.

The trial drug pacritinib (in development by CTI BioPharma) has been placed on full clinical hold by the FDA due to concerns over the safety of the drug. Analysis of data from clinical trials that were ongoing show a detrimental effect on survival and patient deaths from causes including intracranial hemorrhage, cardiac failure and cardiac […]

Stay up to date

Read the Canadian MPN Group newsletter for the latest in the field.

Watch Dr Vikas Gupta speak about Stem Cell Transplant for Myelofibrosis in the JAK2 Inhibitor Era.

Download the new MPN eSimple app.

We need your help

The Canadian MPN Group relies on donor contributions to keep our work going. Can you help?

Twitter Feed